.25 mg of semaglutide Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) semaglutide injection .25 mg Wegovy

In the first few weeks on the drug, you may experience mild side effects as your body starts to adjust to the medication

Wegovy often results in greater weight loss than metformin

Bioelectrical impedance (InBody, smart scales)

doi:10.3389/fneur.2022.844697 Hu EH, Tsai ML, Lin Y, Chou TS, Chen TH

Results: Oral semaglutide reduced HbA1c levels compared to placebo Oral semaglutide patients experienced significant weight loss compared to those on placebo The primary outcome (composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) occurred in 3.8% of patients in the oral semaglutide group and 4.8% in the placebo group, which showed that cardiovascular safety of oral semaglutide was non-inferior to placebo